A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Gh Research PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 3,200 shares of GHRS stock, worth $26,656. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,200
Previous 200 1500.0%
Holding current value
$26,656
Previous $2,000 1750.0%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$10.5 - $14.81 $1.53 Million - $2.15 Million
145,284 Added 1190.07%
157,492 $1.84 Million
Q1 2024

May 15, 2024

SELL
$5.34 - $11.09 $454,038 - $942,938
-85,026 Reduced 87.44%
12,208 $130,000
Q4 2023

Feb 14, 2024

SELL
$5.26 - $11.04 $371,813 - $780,384
-70,687 Reduced 42.1%
97,234 $563,000
Q3 2023

Nov 14, 2023

BUY
$9.8 - $14.15 $228,830 - $330,402
23,350 Added 16.15%
167,921 $1.69 Million
Q2 2023

Aug 14, 2023

BUY
$7.88 - $12.74 $102 - $165
13 Added 0.01%
144,571 $1.72 Million
Q1 2023

May 15, 2023

SELL
$6.02 - $10.92 $6.84 Million - $12.4 Million
-1,136,561 Reduced 88.72%
144,558 $1.16 Million
Q4 2022

Feb 14, 2023

SELL
$9.2 - $13.5 $64,243 - $94,270
-6,983 Reduced 0.54%
1,281,119 $12.5 Million
Q3 2022

Nov 14, 2022

SELL
$10.15 - $16.15 $155,985 - $248,193
-15,368 Reduced 1.18%
1,288,102 $15 Million

Others Institutions Holding GHRS

About GH Research PLC


  • Ticker GHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,020,800
  • Market Cap $433M
  • Description
  • GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...
More about GHRS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.